CorMedix (CRMD) Q4 2024 Earnings Call Transcript CRMD earnings call for the period ending December 31, 2024.
Which stocks are experiencing notable movement on Tuesday? Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Let's uncover which stocks are experiencing notable gaps during today's session. The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.
Which stocks are moving before the opening bell on Tuesday? Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled Small caps took another step down this past week as geopolitical events dampened sentiment.
3 Value Stocks That Are Backed By The World’s Largest Activist Hedge Fund Sometimes, hedge funds make risky decisions. But these stocks are at the lower end of the exposure risk spectrum.
Top movers in Friday's after hours session As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Elliott Investment Management Buys Wolfspeed Stock, Bets Against Nvidia In Q4 Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure.
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.
Smaller Cap Biotechs Are In Season: How Are We Doing? SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
CorMedix (CRMD) Q3 2024 Earnings Call Transcript CRMD earnings call for the period ending September 30, 2024.
Biotech Momentum Trades For The Q4 Rally The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.
Biotech Stocks : Are You A Trader Or A Longer Term Investor? Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.
CRMD Stock Earnings: Cormedix Meets EPS, Misses Revenue for Q2 2024 CRMD stock results show that Cormedix met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
